293 related articles for article (PubMed ID: 18711705)
21. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
22. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
23. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Hunsche E
Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
[TBL] [Abstract][Full Text] [Related]
24. Adverse Drug Events Involving COX-2 Inhibitors.
Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
[TBL] [Abstract][Full Text] [Related]
25. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
[TBL] [Abstract][Full Text] [Related]
26. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease.
Shorr RI; Ray WA; Daugherty JR; Griffin MR
Arch Intern Med; 1993 Jul; 153(14):1665-70. PubMed ID: 8333804
[TBL] [Abstract][Full Text] [Related]
27. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
Dai C; Stafford RS; Alexander GC
Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363
[TBL] [Abstract][Full Text] [Related]
28. Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
Harley C; Wagner S
Manag Care Interface; 2003 Oct; 16(10):38-45. PubMed ID: 14606259
[TBL] [Abstract][Full Text] [Related]
29. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Wolfe F; Michaud K; Burke TA; Zhao SZ
J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.
Velentgas P; West W; Cannuscio CC; Watson DJ; Walker AM
Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):641-52. PubMed ID: 16392153
[TBL] [Abstract][Full Text] [Related]
31. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
[TBL] [Abstract][Full Text] [Related]
32. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
Moride Y; Ducruet T; Rochon S; Lavoie F
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914
[TBL] [Abstract][Full Text] [Related]
33. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
McCarthy DM
Eur J Surg Suppl; 2002; (587):89-99. PubMed ID: 16144207
[TBL] [Abstract][Full Text] [Related]
34. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
[TBL] [Abstract][Full Text] [Related]
35. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis.
Ofman JJ; Badamgarav E; Henning JM; Knight K; Laine L
Am J Med; 2004 Jun; 116(12):835-42. PubMed ID: 15178499
[TBL] [Abstract][Full Text] [Related]
36. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
[TBL] [Abstract][Full Text] [Related]
37. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
Hippisley-Cox J; Coupland C; Logan R
BMJ; 2005 Dec; 331(7528):1310-6. PubMed ID: 16322018
[TBL] [Abstract][Full Text] [Related]
38. [COX-2 inhibitors--one step forward and two steps back].
Evensen S; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
[TBL] [Abstract][Full Text] [Related]
39. The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis.
Yilmaz H; Gürel S; Ozdemir O
Turk J Gastroenterol; 2005 Sep; 16(3):138-42. PubMed ID: 16245223
[TBL] [Abstract][Full Text] [Related]
40. Bleeding complications in patients on celecoxib and warfarin.
Chung L; Chakravarty EF; Kearns P; Wang C; Bush TM
J Clin Pharm Ther; 2005 Oct; 30(5):471-7. PubMed ID: 16164494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
